Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone to Re-sensitize NSCLC to Anti-PD1
NCT04037462Phase 2Terminated
- Sponsor
- VA Office of Research & Development
- Start
- Jul 2021
- Primary completion
- Feb 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dexamethasone in non-small cell lung cancer (NSCLC), sponsored by VA Office of Research & Development. Started Jul 2021; status: terminated.
02
Drugs
dexamethasone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04037462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04037462.